Ge Long Hui·2025-08-18 03:13Group 1 - The core viewpoint of the news is that the A-share market saw a collective rise in weight-loss drug concept stocks, driven by the accelerated approval of Wegovy by the FDA for treating certain liver conditions [1][2]. - Han Yu Pharmaceutical (300199) experienced a significant increase of over 14%, while other companies like Jin Kai Biotechnology and Shengnuo Bio rose by over 12% and 6% respectively [1][2]. - Novo Nordisk's stock rose over 6% in after-hours trading following the FDA's announcement regarding Wegovy [1]. Group 2 - The following companies showed notable stock performance: - Han Yu Pharmaceutical (300199) with a rise of 14.66% and a total market value of 26.4 billion [2]. - Jin Kai Biotechnology (301509) increased by 12.28% with a market value of 5.1 billion [2]. - Shengnuo Bio (688117) rose by 6.00% and has a market value of 7.229 billion [2]. - Yangguang Nuohuo (688621) increased by 4.37% with a market value of 8.96 billion [2]. - ST Nuotai (688076) rose by 4.08% with a market value of 15 billion [2]. - Other companies like Zhongsheng Pharmaceutical and Kangyuan Pharmaceutical also saw increases close to 4% [1][2].